Monoclonal antibody given to preterm babies may reduce wheeze later

(American Thoracic Society) Preterm babies given the monoclonal antibody palivizumab to prevent respiratory syncytial virus (RSV) also appear less likely to develop recurrent wheeze, at least until the age of six, according to new research published online, ahead of print in the American Thoracic Society's American Journal of Respiratory and Critical Medicine.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news